[go: up one dir, main page]

AR011192A1 - Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma - Google Patents

Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma

Info

Publication number
AR011192A1
AR011192A1 ARP980101150A ARP980101150A AR011192A1 AR 011192 A1 AR011192 A1 AR 011192A1 AR P980101150 A ARP980101150 A AR P980101150A AR P980101150 A ARP980101150 A AR P980101150A AR 011192 A1 AR011192 A1 AR 011192A1
Authority
AR
Argentina
Prior art keywords
prostaglandine
preparing
compositions including
medicinal product
ophthalmic compositions
Prior art date
Application number
ARP980101150A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR011192A1 publication Critical patent/AR011192A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Una composicion que comprende un agente activo de prostaglandina, la cual es seleccionada del grupo que consiste de prostaglandina, metabolitos de losmismos, derivados de los mismos, sales de los mismos, y mezclas de los mismos; unconserv ador oftálmico; un agente de ajuste de tonicidad noionico, en donde este agente de ajuste de tonicidad no ionico está presente en una concentracion suficiente para ajustar la tonicidad de la composicion eincrementar la efectividad delconservador; y un vehículo oftálmicamente aceptable. Dichas composiciones exhiben una reduccion mejorada de (IOP) dela presion intraocular y en la eficacia mejorada del conservador.
ARP980101150A 1997-03-17 1998-03-13 Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma AR011192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
AR011192A1 true AR011192A1 (es) 2000-08-02

Family

ID=38729083

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960102868A AR002194A1 (es) 1997-03-17 1996-06-03 Instrumento computarizado para el analisis del movimiento.
ARP980101150A AR011192A1 (es) 1997-03-17 1998-03-13 Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP960102868A AR002194A1 (es) 1997-03-17 1996-06-03 Instrumento computarizado para el analisis del movimiento.

Country Status (32)

Country Link
EP (1) EP0969846B2 (es)
JP (2) JP4920124B2 (es)
KR (1) KR100555818B1 (es)
CN (1) CN1236775C (es)
AR (2) AR002194A1 (es)
AT (1) ATE257385T1 (es)
AU (1) AU738781B2 (es)
BR (2) BRPI9816218B1 (es)
CA (1) CA2280089C (es)
CL (1) CL2009001870A1 (es)
CO (1) CO4940427A1 (es)
CY (1) CY2526B1 (es)
CZ (1) CZ299833B6 (es)
DE (1) DE69820997T3 (es)
DK (1) DK0969846T4 (es)
EE (1) EE04091B1 (es)
ES (1) ES2214706T5 (es)
HU (1) HU228896B1 (es)
ID (1) ID22389A (es)
IL (1) IL131041A0 (es)
MY (1) MY122237A (es)
NO (1) NO327713B1 (es)
NZ (1) NZ337322A (es)
PE (1) PE61899A1 (es)
PL (1) PL197509B1 (es)
PT (1) PT969846E (es)
RU (1) RU2197970C2 (es)
SI (1) SI0969846T2 (es)
TW (1) TW527187B (es)
UA (1) UA63938C2 (es)
WO (1) WO1998041208A1 (es)
ZA (1) ZA982188B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ATE442849T1 (de) * 2004-03-18 2009-10-15 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol- derivat
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
ES2460967T3 (es) * 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
CN101420934B (zh) * 2006-03-17 2014-03-19 庄臣及庄臣视力保护公司 用于使氧化不稳定的组合物稳定的方法
KR20090082401A (ko) * 2006-10-31 2009-07-30 알콘 리서치, 리미티드 안 질환 치료용 ｐａｉ－１ 결합 조절제
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
JP5640207B2 (ja) * 2007-10-08 2014-12-17 セラオプティクスＴｈｅｒａｏｐｔｉｃｓ 水性眼用処方物
EP2420223B1 (en) * 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CN104114152A (zh) 2011-12-07 2014-10-22 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
CN113164043B (zh) * 2018-09-21 2024-10-22 奥夫博医疗创新有限公司 用于青光眼的组合物和方法
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
AU1427592A (en) * 1991-02-07 1992-09-07 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
WO1995030420A1 (en) * 1994-05-06 1995-11-16 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
NZ337322A (en) 2001-05-25
SI0969846T1 (en) 2004-06-30
NO994481D0 (no) 1999-09-16
PL197509B1 (pl) 2008-04-30
ES2214706T5 (es) 2011-02-02
EP0969846B1 (en) 2004-01-07
ID22389A (id) 1999-10-07
HU228896B1 (en) 2013-06-28
AR002194A1 (es) 1998-01-07
KR100555818B1 (ko) 2006-03-03
TW527187B (en) 2003-04-11
HUP0002194A2 (hu) 2000-12-28
DK0969846T4 (da) 2010-12-20
RU2197970C2 (ru) 2003-02-10
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
DK0969846T3 (da) 2004-04-13
DE69820997T3 (de) 2011-10-06
EP0969846B2 (en) 2010-08-25
CY2526B1 (en) 2006-02-08
CN1236775C (zh) 2006-01-18
EP0969846A1 (en) 2000-01-12
CA2280089C (en) 2009-03-03
EE9900410A (et) 2000-04-17
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
HUP0002194A3 (en) 2012-08-28
UA63938C2 (uk) 2004-02-16
CZ325799A3 (cs) 2000-01-12
NO994481L (no) 1999-09-16
ATE257385T1 (de) 2004-01-15
AU7035398A (en) 1998-10-12
BR9808016A (pt) 2000-03-08
IL131041A0 (en) 2001-01-28
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
CN1249687A (zh) 2000-04-05
HK1026841A1 (en) 2000-12-29
MY122237A (en) 2006-04-29
CZ299833B6 (cs) 2008-12-10
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
EE04091B1 (et) 2003-08-15
JP2010043110A (ja) 2010-02-25
PE61899A1 (es) 1999-06-30
DE69820997D1 (de) 2004-02-12
NO327713B1 (no) 2009-09-14
PT969846E (pt) 2004-05-31
PL335168A1 (en) 2000-04-10
CL2009001870A1 (es) 2010-01-22
JP4920124B2 (ja) 2012-04-18
BRPI9816218B1 (pt) 2016-04-12
KR20000076330A (ko) 2000-12-26
ES2214706T3 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
AR011192A1 (es) Composiciones oftalmicas que comprenden una prostaglandina y el uso de los mismos en la preparacion de un medicamento para tratar glaucoma
US5849792A (en) Storage-stable prostaglandin compositions
AU2002312221B2 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
ES2213504T1 (es) Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
MXPA96003560A (es) Composiciones de prostaglandinas estables enalmacenamiento
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
AR033688A1 (es) Composicion parenteral reconstituible
ES2042625T3 (es) Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
KR960700039A (ko) β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
KR100260061B1 (en) Vitamin e drop
US6291519B1 (en) Method of preventing damage to eye tissue
AR009028A1 (es) Composiciones farmaceuticas, un procedimiento para preparar dichas composiciones y utilizacion de dichas composiciones en el tratamiento deenfermedades oftalmicas y metodos para tratar dichas enfermedades
AR032138A1 (es) Derivados de 6-hidroxi-indazol, una composicion oftalmica, y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de glaucoma
JPH09506081A (ja) 医薬としてのシクロペンタンヘプタンまたはヘプテン酸，２−アリールアルキルまたはアリールアルケニルおよび誘導体
NO933140D0 (no) Legemiddel for lokal anvendelse paa oeyet for behandling avforhoeyet intraokulart trykk
KR20220131878A (ko) 세티리진 및 토코페솔란을 포함하는 안과용 조성물
US4126695A (en) Anti-glaucoma composition and method
ES2392221T3 (es) Composición farmacéutica que comprende una prostaglandina
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
JPH09507229A (ja) ７−［カルボキシアルキルまたはアルケニル］−６−［アルキルまたはアルケニル］−３−オキソ−２，４−ジオキソビシクロ［３．２．１］オクタンおよびその誘導体
KR950702422A (ko) (에스)-티몰롤 헤미하이드레이트를 함유하는 안약 국소 조성물(ophthalmic topical composition containing (s)-timolol hemihydrate)
US5654335A (en) Topical use of ethyl ethacrynate for glaucoma treatment
JPS5513241A (en) Remedy for glaucoma

Legal Events

Date Code Title Description
FC Refusal